Staff

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to KaziaSYDNEY, Sept. 22, 2026 /PRNewswire/ --...

Rhelion Life Sciences’ Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate

A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property...

Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices

New agreement brings innovative diagnostic, shock wave therapy, and remote monitoring solutions to more than 2,000 member practices across the...

error: Content is protected !!